Regulatory Compliance

London and St Helier, Jersey – September 21, 2026 -- Bloomsbury Money Group has appointed Thomas Holst, a former SAP health-technology engineer with more than a decade of experience, as Chief Technology Officer to lead the build-out of its multi-jurisdiction banking platform.

Holst will unify fiat, digital assets and payment rails onto one platform

Holst joins from SAP's health technology ecosystem in Germany, where he spent 13 years building data-intensive, privacy-critical software for hospitals and research institutions and the cloud infrastructure supporting it. At Bloomsbury Money, he will oversee technology strategy, engineering and platform architecture as the group consolidates its multi-currency accounts, foreign exchange, cross-border payments and regulated virtual asset services onto a single infrastructure designed to operate under one standard of control across multiple regulatory regimes.

New Taipei City – September 21, 2026 -- UD info's DB Series SSD Drives have achieved FIPS 140-3 validation from the National Institute of Standards and Technology's Cryptographic Module Validation Program, with NIST Certificate No. 5479 issued August 12, 2026, confirming Overall Level 2 status.

Certificate confirms Overall Level 2 validation for DB Series cryptographic module

The validation provides independent third-party assurance that the DB Series meets federal cryptographic security requirements, addressing procurement mandates in government, critical infrastructure, and other regulated sectors. NIST CMVP validation is a common prerequisite for federal and defense-adjacent storage procurement in the United States.

Melbourne – September 21, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has signed a strategic agreement to merge with ITM Isotope Technologies Munich SE in a deal valuing ITM at US$1.65 billion upfront on a cash-free, debt-free basis, with up to US$700 million in additional contingent consideration tied to regulatory and sales milestones.

Deal structures $1.25 billion in Telix stock alongside debt assumption

Under the agreement, ITM shareholders will receive approximately US$1.25 billion in the form of 105.8 million Telix shares priced at US$11.84 per share, released as Nasdaq-listed ADRs following escrow periods of up to 15 months. Telix will additionally assume US$302 million of ITM net debt at closing, with US$96 million allocated to management equity rollover and transaction expenses. Upon completion, existing Telix shareholders will hold roughly 76.3% of the combined company, with ITM shareholders holding approximately 23.7%.

Seattle – September 21, 2026 -- Convera and JustLogin have partnered to embed regulated cross-border payroll and business payment capabilities directly into JustLogin's HR platform, enabling companies to initiate payments in up to 16 currencies across Singapore and Southeast Asia.

Partnership targets $105 billion regional B2B payments opportunity

Southeast Asia's B2B payments market was valued at approximately USD 44.5 billion in 2024 and is projected to exceed USD 105 billion by 2033, according to figures cited by the companies. The integration positions JustLogin's HR platform to capture a share of that growth by letting customers manage payroll disbursement without leaving their existing workflow.

Shanghai – September 21, 2026 -- Antengene Corporation Limited (SEHK: 6996.HK) has dosed the first patient in China in its pivotal Phase III CLINCH-3 study evaluating ATG-022, a CLDN18.2 antibody-drug conjugate, as monotherapy for CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Breakthrough Therapy Designation accelerated the trial's launch

China's National Medical Products Administration granted ATG-022 Breakthrough Therapy Designation, which the company says streamlined regulatory communications and enabled the rapid start of CLINCH-3. The randomized, controlled, open-label multicenter study is initiated in China and planned for expansion into a multi-regional clinical trial, with Professor Lin Shen of Peking University Cancer Hospital serving as principal investigator. The study compares ATG-022 against treatment of investigator's choice, targeting a future marketing approval application.

Singapore – September 21, 2026 -- Specialised Therapeutics (ST) has expanded its partnership with Incyte Biosciences International to commercialise, distribute, and register ruxolitinib cream, marketed as Opzelura, in Australia.

ST gains rights to market Opzelura for vitiligo and atopic dermatitis in Australia

Under the expanded agreement, Incyte will continue to develop and manufacture ruxolitinib cream, a topical Janus kinase (JAK) inhibitor, while ST takes on regulatory submissions, medical affairs, marketing, and distribution across the Australian market. The drug is approved in the U.S. and European Union for treating non-segmental vitiligo and mild-to-moderate atopic dermatitis in patients who do not respond adequately to standard topical therapies.

Urbandale, Iowa – September 21, 2026 -- Small businesses in the Des Moines metro should secure general liability insurance first, followed by property coverage and workers' compensation, according to insights from Ben Buenzow, an insurance expert at Buenzow Insurance Group, featured in a HelloNation article.

General liability insurance forms the first line of financial defense for small operators

The coverage protects companies against claims of bodily injury or property damage stemming from business operations, addressing risks from customers, vendors, or visitors. Legal costs and settlements tied to such claims can be significant enough to threaten a small firm's cash flow without this protection in place.

Atlanta – September 21, 2026 -- Siemba has launched automated testing for insecure direct object reference (IDOR) flaws, cutting the time to scan a 200-endpoint API collection to under an hour, a task the company says has typically taken human testers days or weeks.

IDOR ranks first among OWASP's API Security Top 10 risks

IDOR, classified by OWASP as broken object level authorization, occurs when an endpoint fails to verify that a caller-supplied identifier belongs to them, allowing a single changed number in a request to expose another user's data. Siemba's Chief Security Officer Sandhya Prashanth said the flaw "drives a huge share of real-world breaches" and requires little more than systematic testing across every endpoint to detect.

New York and Suzhou, China – September 21, 2026 -- Accro Bioscience Inc. has dosed its first patient in a Phase IIb trial testing AC-101, a selective RIPK2 inhibitor, in patients with moderate-to-severe ulcerative colitis (UC).

Trial spans roughly 50 clinical sites with three treatment arms

The multicenter, double-blind, placebo-controlled study is designed across approximately 50 clinical sites and includes two AC-101 dose cohorts plus a placebo control arm. The primary endpoint is clinical remission rate at Week 12, with exploratory endpoints covering histologic remission and long-term maintenance of clinical and histologic remission.

Beijing – September 21, 2026 -- Nearly 400 domestic and international delegates gathered at the Beijing Municipal Administrative Center (BMC) on September 17 as the Beijing Green Development Forum 2026 opened, unveiling a new blue book on the capital's green economy and a standards-led transition initiative backed by more than 20 institutions.

Hosted by Asia Data Group and organized by ADG Expo Group, the forum carried the theme "Green Empowerment, Low-Carbon Symbiosis" and drew support from Global Honorary Partner Huaxia Bank and strategic partner Beijing Energy Holding Co., Ltd. International bodies including the World Green Design Organization, C40 Cities Climate Leadership Group, and the Center for China & Globalization backed the event.